Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- From Phase III Trials to Commercialization Partnerships, MindRank's AI Drug Development Value Comes into FocusHong Kong, Oct 9, 2026 - As AI Drug Development Approaches Commercialization, MindRank Marks a Key Business Milestone How much value can AI create in the discovery and development of new medicines' For investors following the sector, the answer lies in tangible progress in drug development and business execution. A platform’s ability to consistently generate drug candidates, advance lead assets through clinical development and secure recognition from industry partners provides an important basis for assessing an AI drug developer’s growth potential. The recently announced commercialization partnership by MindRank AI Ltd. (MindRank, hereinafter “MindRank”) offers a new window into this question. On September 28, 2026, MindRank announced an exclusive commercialization partnership with 3SBio (01530.HK) subsidiaries Sunshine Mandi and Wansheng Pharmaceutical for MDR-001, its internally developed, AI-designed oral small-molecule GLP-1 receptor agonist. Covering mainland China, Hong Kong and Macau, the agreement carries a potential total transaction value of up to RMB1.75 billion, alongside a substantial share of sales revenue. MDR-001 is currently undergoing a pivotal Phase III clinical trial in China in adults with obesity or overweight. For MindRank, a clinical-stage AI-native drug discovery and development technology company, the partnership further connects drug development with commercialization planning. It lays the groundwork for marketing its lead asset following potential approval and establishes a clearer pathway for translating AI-driven research into commercial value. As its lead asset advances through pivotal clinical development, MindRank has begun preparing for post-approval marketing and channel coverage, extending the product’s development pathway into commercialization. Under the agreement, Sunshine Mandi and Wansheng Pharmaceutical will provide exclusive, comprehensive services and distribution across all channels following MDR-001’s launch. MindRank will retain all rights, title and interests in the product’s intellectual property and remain responsible for clinical development, regulatory submissions, manufacturing and supply. The transaction includes up to RMB150 million in payments for collaboration rights, up to RMB1.6 billion in royalty payments upon the fulfillment of agreed conditions, and a substantial share of sales revenue. From a business-model perspective, the agreement establishes a clear division of responsibilities. MindRank will continue investing in research and product development, while its partners will provide exclusive, comprehensive services and distribution across all channels within the agreed territories following regulatory approval and launch. In an industry that requires sustained investment, this collaboration could help MindRank retain its core asset rights while drawing on its partners’ commercial capabilities to support launch preparations and focus its own resources on strengthening its core capabilities. The partners’ willingness to make commercialization arrangements for an investigational drug also provides a new reference point for assessing its potential industry value. Clinical data address whether a product merits further development, while commercial partnerships indicate whether industry participants are willing to take part in its subsequent development. Together, these elements make MindRank’s growth story more tangible. A Lead Asset in Phase III Provides a Clearer Basis for Assessing AI-Driven R&D Capabilities The core asset underpinning the partnership is MDR-001, which continues to advance through development. In February 2026, MindRank announced that the first participant had been dosed in MOBILE, its Phase III clinical trial of MDR-001. According to the company, the multicenter, randomized, double-blind, placebo-controlled study plans to enroll approximately 750 participants across around 50 clinical centers in China to further evaluate the product’s long-term efficacy and safety. This means the evidence available to assess MindRank’s AI-driven R&D capabilities now extends to larger-scale, late-stage clinical research. For investors, the lead asset’s entry into Phase III sharpens the focus on several key questions: whether long-term efficacy can be further validated, whether safety and tolerability findings can be sustained, and whether the product can establish clinically meaningful competitive advantages. Previously disclosed Phase IIb findings supported further development. In the study, which enrolled 317 adults with obesity or overweight, participants in the MDR-001 dose groups achieved mean reductions in body weight from baseline of 8.2% to 10.3% after 24 weeks, compared with 2.5% in the placebo group. The rate of treatment discontinuation due to treatment-emergent adverse events was 0.8%. Common adverse events were primarily gastrointestinal and mostly mild to moderate. These findings remain subject to further validation in subsequent studies. For weight-management medicines, product value depends on a combination of weight-loss efficacy, long-term safety, tolerability and ease of use. Compared with the injectable peptide-based GLP-1 medicines that currently dominate the market, MDR-001’s oral small-molecule formulation can significantly improve medication adherence, while its large-scale manufacturing costs are substantially lower than those of peptide-based medicines, offering considerable market potential and commercial value. These attributes provide a promising direction for its future product positioning, although translating them into a competitive advantage will require continued accumulation of clinical evidence. Beyond progress in product development, R&D efficiency is another important lens through which to assess MindRank. According to the company, MDR-001 progressed from project initiation to preclinical candidate (PCC) nomination in just eight months, during which approximately 80 small molecules were synthesized. Its investigational new drug (IND) application was cleared in the United States within 19 months of project initiation and MDR-001 advanced to Phase III in China in approximately 4.5 years. In its July 2026 financing announcement, the company further disclosed that cumulative direct R&D investment in the program, from initiation through the start of Phase III in China, totaled approximately US$23 million. These timelines and investment figures provide a more concrete basis for understanding how MindRank organizes drug discovery and development. For drug developers, development timelines and funding requirements directly affect how many programs they can advance, how long they can sustain development and how they allocate resources to subsequent work. AI’s commercial significance must also be assessed within these real-world R&D constraints. As a flagship application of MindRank’s AI-driven drug discovery and development system, MDR-001 offers a traceable development pathway: from molecular design to clinical research and, subsequently, commercialization partnerships. The platform’s capabilities are beginning to be tested through tangible business outcomes. This provides capital markets with a more useful basis for understanding the company’s technology value than descriptions of algorithms or model parameters alone. Beyond the Lead Asset, Long-Term Growth Depends on Sustained Platform Output MDR-001 is the central focus of MindRank’s business progress at this stage, while the company’s long-term growth potential also depends on its ability to continue developing new drug assets. According to the MindRank, its end-to-end AI drug development engine, MAP (Molecule Arts Platform), integrates biology, chemistry, computation, experimental validation and clinical learning into a unified drug discovery and development system. In July 2026, the company announced that it had completed a cumulative US$52 million Series B financing in stages, with proceeds earmarked for further platform development and the advancement of its clinical and preclinical pipeline. In September 2026, the company formally launched Intera (Intelligence Era), its life-sciences foundation model system, and released a technical report on InteraFold-Chem, the first model in the InteraFold series. From an operating perspective, platform development and pipeline advancement have the potential to reinforce each other. R&D programs bring real-world problems and experimental feedback to the platform, while platform iterations support the discovery and optimization of subsequent programs. Ultimately, the platform’s value must be reflected in sustained output: its ability to advance more molecules with development potential across different targets and disease areas, gradually building a business supported by multiple assets. MindRank has already expanded beyond metabolic diseases. In March 2025, the company disclosed that MRANK-106, an oral dual inhibitor of WEE1 and YES1, had received IND approval in the U.S. in oncology. This development provides another case through which to assess the applicability of its AI platform across different R&D areas, although the product’s potential remains subject to subsequent clinical validation. In earlier-stage research, the company disclosed in April 2026 that a collaborative study on drug discovery for Alzheimer’s disease, conducted by MindRank, the University of Macau and Imperial College London, had been published in Nature Biomedical Engineering. The work combined AI screening with experimental validation to identify small molecules meriting further investigation, demonstrating the company’s research capabilities and exploration at the forefront of drug discovery for complex diseases. These programs are at different stages, and their contributions to the company’s value need to be assessed separately. MDR-001 remains the main focus of current clinical development and commercialization preparations, while other pipeline programs and research support the platform’s broader applicability and long-term project portfolio. As more programs deliver verifiable progress, outside observers will be better positioned to assess whether the company can consistently replicate its R&D capabilities. Viewed through this lens, the recent commercialization partnership offers an opportunity to reassess MindRank. Its lead asset has entered pivotal clinical development, partners are participating in commercialization preparations at an early stage, financing supports continued R&D, and its presence across multiple areas preserves opportunities for future growth. These interconnected developments make the company’s development trajectory easier for capital markets to understand. MDR-001 remains in clinical development and has not yet received marketing approval. Its future value realization depends on clinical results, regulatory approval and commercial execution. Nevertheless, the business progress achieved to date provides a more concrete basis for assessing MindRank. For investors following opportunities at the intersection of AI and innovative medicines, the central question worth tracking is whether the company can progressively translate its established R&D capabilities into more verifiable drug assets and commercial outcomes.
- World-Class Oncology on a Budget: Why Global Patients Choose India for Gastric CancerIndia provides affordable gastric cancer treatment with advanced technology and expert oncologists.
- Antengene Corporation LimitedAntengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- Everest MedicinesEverest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical DevelopmentLakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines Appointments support continued advancement of Everest's mRNA...
- Retension Pharmaceuticals Announces Pricing of Initial Public OfferingRetension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the pricing of its upsized initial public offering of 3,750,000 shares of its common stock at an initial public offering price of $12.00 per share. The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million. All shares of common stock are being offered by Retension. Retension has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on or about October 13, 2026, subject to the satisfaction of customary closing conditions. The shares are expected to begin trading on October 9, 2026 on the Nasdaq Capital Market under the ticker symbol “RTSN.”
- AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARDWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline.
- Innovent BiologicsInnovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye DiseaseSYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) — Innovent Biologics, Inc. ("Innovent")...
- Ribo soumet une demande d'essai clinique européen pour une étude de phase I pour l'ARNsi RBD3133 ciblant l'INHBESUZHOU, Chine et MÖLNDAL, Suède, 9 octobre 2026 -- Suzhou Ribo Life Science (06938.HK) et sa filiale Ribocure Pharmaceuticals AB (désignées collectivement sous le nom de « Ribo ») ont annoncé avoir déposé une demande d'essai clinique de phase I (CTA) auprès de l'Union...
- Ribo reicht einen Antrag auf eine europäische klinische Studie der Phase I für die gegen INHBE gerichtete siRNA RBD3133 einSUZHOU, China und MÖLNDAL, Schweden, 9. Oktober 2026 -- Suzhou Ribo Life Science (06938.HK) und seine Tochtergesellschaft Ribocure Pharmaceuticals AB (zusammen als „Ribo" bezeichnet) gaben bekannt, dass sie in der EU erfolgreich einen Antrag auf Durchführung einer klinischen...
- THE ROSEN LAW FIRM, P. A.UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November...
- Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetPharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global, randomized, double-blind, placebo-controlled crossover study evaluating oral deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of HAE attacks in adolescents and adults have been published in The Lancet (Journal Impact Factor: 109.0).
- Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L ProductionNorthwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and the UK National Health Service Blood and Transplant ("NHSBT") announce that...